Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Post by straightupon Feb 17, 2012 10:47am
279 Views
Post# 19549094

AM

AM

I found this company after Peter Hodson who used to be with Sprott and now runs 5I Research tweeted about the dividend raise. He did not make a recommendation on it but just by mentioning it was bringing it to subscribers attention. So what does that tell you?

He loves undervalued companies that are growing and returning profits to shareholders. Sounds like AM to me. Just too small for now for full coverage. 

Bullboard Posts